Results 101 to 110 of about 74,341 (223)

BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

, 2005
The BCR-ABL tyrosine kinase inhibitor imatinib has greatly improved the outcome for patients with chronic myeloid leukaemia (CML). Unfortunately, mutations causing resistance to imatinib are leading to relapses in some patients. In addition to inhibiting
Doggrell, Sheila A., Doggrell, Sheila
core   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, Volume 117, Issue 6, Page 1421-1441, December 2026.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

İmatinib Mesilat Kaynaklı Kardiyo-Toksisitede Astaksantinin Etkileri [PDF]

, 2020
Aim: Imatinib mesylate is a tyrosine kinase inhibitor and is approved as a standard first-line therapy of chronic myeloid leukemia. Oxidative stress, as well as intracellular calcium overload and mitochondrial dysfunction, play an important role in ...
Övey, İshak Suat, Öncel, Can Ramazan
core   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

European Journal of Haematology, Volume 117, Issue 6, Page 1485-1499, December 2026.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

New Bcr-Abl-independent mechanisms of resistance to imatinib treatment in chronic myelogenous leukaemia patients [PDF]

, 2008
Although rare in chronic phase myeloid leukemia (CML), primary or acquired resistance to the treatment with tyrosine kinase inhibitors (TKI) may be observed in the advanced phases of disease.
Esposito, Nicola
core   +1 more source

Cheek Reconstruction With a Free Internal Mammary Perforator (IMAP) Flap in an African American Patient With Recurrent Dermatofibrosarcoma

Clinical Case Reports, Volume 14, Issue 11, November 2026.
ABSTRACT Traditional flaps dominate head and neck reconstruction; however, the free internal mammary artery perforator (IMAP) flap offers excellent pliability, hidden donor‐site closure, and favorable cervicofacial color match. We report the use of a free IMAP flap for cheek reconstruction in an African American patient with recurrent ...
Olivier F. Noel, Carla I. Becerra, Gidarell Bryant, James E. Clune   +3 more
wiley   +1 more source

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1315-1325, November 2026.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi, Mwila Mulubwa, Mmakwena M. Mmonwa, Mathew Njoroge, Liezl Krugmann, Kelly Chibale   +5 more
wiley   +1 more source

Profile of imatinib in pediatric leukemia

, 2014
Michael J BurkeDepartment of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI, USAAbstract: Using targeted therapy for treatment of cancer has become the paradigm to which clinical ...
Burke MJ
core  

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1338-1347, November 2026.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

A Case of Recurrent Pulmonary Tumor Thrombotic Microangiopathy Associated With Gastric Adenocarcinoma Following Imatinib Discontinuation

Pulmonary Circulation
Pulmonary tumor thrombotic microangiopathy (PTTM) is a severe and fatal disease that rapidly causes pulmonary hypertension (PH). While imatinib shows potential for treating PH related to PTTM, it remains unclear if imatinib should continue or be ...
Atsumasa Kurozumi, Shun Minatsuki, Masaru Hatano, Takayuki Tsujimoto, Gota Fujisawa, Satoshi Ishii, Hiroki Yagi, Mai Shimbo, Masako Ikemura, Mitsuhiro Fujishiro, Norihiko Takeda   +10 more
doaj   +1 more source